Starsource Multitrade
BSE: STARSOURCE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Starsource Multitrade's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Starsource Multitrade Limited is an Indian multi-product trading house listed on the BSE SME platform. The company facilitates the supply of agricultural products, industrial chemicals, and consumer goods by bridging the gap between bulk producers and end-users.
Business Model
The company operates on a high-volume, low-margin trading model, sourcing goods from manufacturers and wholesalers for distribution to industrial and retail clients. It focuses on supply chain logistics and inventory turnover to maintain operational efficiency.
Growth Outlook
The company aims to enhance its market presence by expanding its product portfolio and increasing its geographical reach within the domestic Indian market.
Key Risks
- Low Margin Sensitivity. The company's reliance on high-volume, low-margin transactions makes it vulnerable to minor fluctuations in operating costs or pricing pressures.
- Supply Chain Disruptions. As a trading house, the company is susceptible to logistical bottlenecks and supply chain inefficiencies that could impact inventory turnover.
- Market Competition. The trading sector is highly fragmented, exposing the company to intense competition from both organised and unorganised players.
- Commodity Price Volatility. Fluctuations in the prices of agricultural products and industrial chemicals can adversely affect the company's profitability and working capital requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Starsource Multitrade and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹13 Cr
TTM · standalone
EPS
₹83.86
TTM · standalone
RETURN ON EQUITY
97.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
96.3%
TTM · standalone
P/E
1.0x
Q1 FY26 · standalone
EV/EBITDA
1.1x
Q1 FY26 · standalone
DEBT TO EQUITY
0.0x
Q2 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Starsource MultitradeSTARSOURCE | ₹12 Cr | 0.96 | 0.98 | — | 450.0% | 97.7% | 96.3% | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q1 FY26
Financials
Starsource Multitrade
BSE: STARSOURCE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Starsource Multitrade's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Starsource Multitrade Limited is an Indian multi-product trading house listed on the BSE SME platform. The company facilitates the supply of agricultural products, industrial chemicals, and consumer goods by bridging the gap between bulk producers and end-users.
Business Model
The company operates on a high-volume, low-margin trading model, sourcing goods from manufacturers and wholesalers for distribution to industrial and retail clients. It focuses on supply chain logistics and inventory turnover to maintain operational efficiency.
Growth Outlook
The company aims to enhance its market presence by expanding its product portfolio and increasing its geographical reach within the domestic Indian market.
Key Risks
- Low Margin Sensitivity. The company's reliance on high-volume, low-margin transactions makes it vulnerable to minor fluctuations in operating costs or pricing pressures.
- Supply Chain Disruptions. As a trading house, the company is susceptible to logistical bottlenecks and supply chain inefficiencies that could impact inventory turnover.
- Market Competition. The trading sector is highly fragmented, exposing the company to intense competition from both organised and unorganised players.
- Commodity Price Volatility. Fluctuations in the prices of agricultural products and industrial chemicals can adversely affect the company's profitability and working capital requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Starsource Multitrade and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹13 Cr
TTM · standalone
EPS
₹83.86
TTM · standalone
RETURN ON EQUITY
97.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
96.3%
TTM · standalone
P/E
1.0x
Q1 FY26 · standalone
EV/EBITDA
1.1x
Q1 FY26 · standalone
DEBT TO EQUITY
0.0x
Q2 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26